QLINEA Stock Overview
Q-linea AB (publ) se dedica al desarrollo de instrumentos y consumibles para el diagnóstico de infecciones en el Reino Unido.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Q-linea AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr2.10 |
| 52 Week High | kr10.30 |
| 52 Week Low | kr2.00 |
| Beta | 1.09 |
| 1 Month Change | -2.33% |
| 3 Month Change | -43.85% |
| 1 Year Change | -67.19% |
| 3 Year Change | -98.64% |
| 5 Year Change | -96.69% |
| Change since IPO | -96.88% |
Recent News & Updates
Recent updates
Here's Why Q-linea (STO:QLINEA) Must Use Its Cash Wisely
Dec 31
Will Q-linea (STO:QLINEA) Spend Its Cash Wisely?
May 07Q-linea (STO:QLINEA) Is In A Good Position To Deliver On Growth Plans
Jan 11We're Hopeful That Q-linea (STO:QLINEA) Will Use Its Cash Wisely
Feb 17
Do Institutions Own Q-linea AB (publ) (STO:QLINEA) Shares?
Dec 26Shareholder Returns
| QLINEA | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | -2.3% | 1.1% | -1.3% |
| 1Y | -67.2% | -8.2% | 11.7% |
Rentabilidad frente al sector: QLINEA obtuvo unos resultados inferiores a los del sector Swedish Medical Equipment , que el año pasado arrojó un rendimiento del -3.8%.
Rentabilidad vs. Mercado: QLINEA obtuvo unos resultados inferiores a los del mercado Swedish, que fue del 4.8% el año pasado.
Price Volatility
| QLINEA volatility | |
|---|---|
| QLINEA Average Weekly Movement | 8.0% |
| Medical Equipment Industry Average Movement | 7.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.5% |
Precio estable de las acciones: QLINEAha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: QLINEALa volatilidad semanal ha disminuido de 16% a 8% en el último año.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 127 | Stuart Gander | https://qlinea.com |
Q-linea AB (publ) se dedica al desarrollo de instrumentos y consumibles para el diagnóstico de infecciones en el Reino Unido. Ofrece ASTar, un sistema de pruebas de susceptibilidad a los antibióticos utilizado para hemocultivos positivos; y sistemas de diagnóstico in vitro para enfermedades infecciosas. La empresa presta servicios a proveedores de atención sanitaria.
Q-linea AB (publ) Fundamentals Summary
| QLINEA fundamental statistics | |
|---|---|
| Market cap | kr245.36m |
| Earnings (TTM) | -kr229.37m |
| Revenue (TTM) | kr6.62m |
37.0x
P/S Ratio-1.1x
P/E RatioIs QLINEA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| QLINEA income statement (TTM) | |
|---|---|
| Revenue | kr6.62m |
| Cost of Revenue | kr3.45m |
| Gross Profit | kr3.18m |
| Other Expenses | kr232.54m |
| Earnings | -kr229.37m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 12, 2024
| Earnings per share (EPS) | -1.96 |
| Gross Margin | 47.98% |
| Net Profit Margin | -3,463.17% |
| Debt/Equity Ratio | 0% |
How did QLINEA perform over the long term?
See historical performance and comparison